Founders & CXOs

Cipla Has a New CEO From Today — IIT Delhi and IIM Ahmedabad Alumnus Achin Gupta Takes Charge as Umang Vohra Ends a Decade at the Helm

By BHC, Editor in Chief · April 03, 2026 · 5 min read

Summary

• Achin Gupta became Cipla's Managing Director and Global CEO on April 1, 2026, succeeding Umang Vohra after a decade. Here is a complete profile of the new leader and what his appointment means for Cipla's next chapter.

India's pharmaceutical sector has a new face at the helm of one of its most significant companies. Effective April 1, 2026, Achin Gupta has taken charge as Managing Director and Global Chief Executive Officer of Cipla Limited — succeeding Umang Vohra, who led the 89-year-old company since 2016. The transition, approved by Cipla's board at its meeting on March 30, follows a structured succession process that has been in motion since October 2025, when Gupta was first named CEO-designate.

"Its legacy of purpose-driven innovation and patient-centric care is deeply inspiring. My focus will be on driving sustainable growth, deepening our impact across markets, and continuing to innovate with purpose."

Cipla is not a small stage. The company is ranked third in India's pharmaceutical market by sales volume, second in South Africa, and fourth in US generic inhalation products. Its humanitarian legacy — most famously, its decision to offer triple HIV/AIDS therapy in Africa for less than a dollar a day in 2001 — has defined its brand globally. The leader who takes the reins of this institution carries not just a commercial mandate, but a moral one.

**Who Is Achin Gupta

Achin Gupta is a product of two of India's most demanding institutions: he holds an MTech in Biochemical Engineering and Biotechnology from IIT Delhi and an MBA from IIM Ahmedabad. His career has spanned the intersection of pharmaceutical operations and strategic management — beginning with consulting at A.T. Kearney, then moving through leadership roles at Abbott Laboratories and two stints at Glenmark Pharmaceuticals across multiple international markets.

He joined Cipla in 2021 as CEO of the One India business — the company's domestic commercial operation. Under his leadership, the India business delivered market-leading profitability, expanded in chronic therapy segments, modernised its retail operations, and entered into global partnerships. In February 2025, he was elevated to Global Chief Operating Officer, taking oversight of commercial markets, API operations, manufacturing, and supply chain. The CEO appointment follows naturally from that operational trajectory.

**What Umang Vohra Built

To understand where Cipla is going under Gupta, it is important to understand what Vohra built. When Vohra took over in 2016, Cipla was a strong but somewhat diffuse organisation — strong in generics, strong in respiratory therapies, but without a fully coherent global growth strategy. Over a decade, Vohra repositioned the company's US portfolio toward speciality generics and complex inhalation products, strengthened digital and manufacturing capabilities, and built a more disciplined approach to capital allocation. He leaves Cipla significantly more focused and more profitable than he found it.

Cipla chairman Dr. Y.K. Hamied, whose family built Cipla into what it is today, praised Vohra's stewardship explicitly: his outstanding contributions combined business success with the humanitarian approach that defines Cipla's identity. That combination — commercial rigour and ethical purpose — is the inheritance Gupta receives.

**The Agenda Ahead

Gupta steps into the role at a moment when Indian pharma is navigating a complex set of challenges and opportunities simultaneously. The semaglutide patent expiry has restructured the diabetes and obesity drug market overnight. The US generics market remains highly competitive and margin-pressured. Evolving regulatory requirements under the revised Schedule M GMP norms and increasing USFDA scrutiny are raising the bar for manufacturing quality. And the next generation of therapies — biosimilars, complex generics, inhalation specialities — requires sustained R&D investment.

At the same time, the domestic India market is growing rapidly in chronic therapies, and Cipla's One India business — which Gupta himself built — is well-positioned to capture that growth. His operational background suggests a leader who will prioritise execution quality, supply chain efficiency, and commercial discipline over bold restructuring moves.

**BHC Perspective

For the Bengaluru Health Community ecosystem, Cipla's leadership transition matters for several reasons. Cipla is one of the most important employers of pharmaceutical talent in India, a significant partner to hospitals and pharmacy chains, and a bellwether for the broader Indian generic pharma industry. How Gupta navigates the semaglutide generic market, manages US regulatory relationships, and positions Cipla for the next wave of complex therapies will be watched closely by the entire ecosystem. We will be tracking Cipla's strategic moves under his leadership throughout 2026.

**Frequently Asked Questions

Q: Who is Cipla's new CEO?
A: Achin Gupta is Cipla's new Managing Director and Global CEO from April 1, 2026. He is an IIT Delhi and IIM Ahmedabad alumnus with over two decades of pharmaceutical experience, including previous roles at Abbott and Glenmark. He joined Cipla in 2021 and previously led its One India business and Global COO functions.

Q: Why did Umang Vohra leave Cipla?
A: Umang Vohra completed his term as MD and Global CEO on March 31, 2026. His departure was a planned succession process, not an early exit. He had led Cipla since 2016 and is credited with significantly expanding its global footprint and improving profitability.

Q: What is Cipla's market position in India?
A: Cipla is ranked third in India's pharmaceutical market by sales volume, second in South Africa, and fourth in US generic inhalation products. The company has revenues exceeding ₹7,500 crore per quarter and a strong position in respiratory therapies and chronic care.